The effects of bisphosphonates on disease activity and bone status in ankylosing spondylitis (BIAS)

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2005
INTERVENTION: Placebo or Alendronate 70 mg weekly CONDITION: Ankylosing Spondylitis (AS) ; Musculoskeletal Diseases ; Ankylosing Spondylitis (AS) PRIMARY OUTCOME: BAS‐G SECONDARY OUTCOME: BASDAI, BASFI and BASRI, ESR, CRP, use of NSAIDs, bone density and vertebral deformity. INCLUSION CRITERIA: Age > 21, stable dose of non‐steroidal anti‐inflammatory drug (NSAID) for last four weeks. Need to fulfil New York Criteria for AS.
Epistemonikos ID: ff24e6d84258666e7ce59f17e64ad604b7b333b6
First added on: Aug 21, 2024